Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Takashi Mizowaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8135-8746; OpenAlex author ID A5023608537. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: none · 2025: 3 papers

Papers 24

  1. Multi-Institutional Phase II Study on the Efficacy and Safety of Dynamic Tumor-Tracking, Moderately Hypofractionated Intensity-Modulated Radiotherapy in Patien… Last author DOI 10.1002/cam4.70648↗
  2. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and pro… Last author DOI 10.1007/s00066-025-02433-9↗
  3. Dosimetric performance of cone beam CT-guided adaptive carbon-ion radiotherapy with daily replanning for pancreatic cancer. Co-author DOI 10.1016/j.ejmp.2025.104991↗
  4. Potential utility of cone-beam CT-guided adaptive radiotherapy under end-exhalation breath-hold conditions for pancreatic cancer. Last author DOI 10.1002/acm2.13827↗
  5. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A pros… Co-author DOI 10.1002/cam4.6470↗
  6. Assessing target localization accuracy across different soft-tissue matching protocols using end-exhalation breath-hold cone-beam computed tomography in patien… Last author DOI 10.1093/jrr/rrad048↗
  7. Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for locally advanced … Last author DOI 10.1186/s13014-023-02288-3↗
  8. Correction: Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for local… Last author DOI 10.1186/s13014-023-02321-5↗
  9. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Co-author DOI 10.1186/s12885-022-09244-6↗
  10. Statistical deformation reconstruction using multi-organ shape features for pancreatic cancer localization. Co-author DOI 10.1016/j.media.2020.101829↗
  11. Statistical shape model-based planning organ-at-risk volume: application to pancreatic cancer patients. Last author DOI 10.1088/1361-6560/abcd1b↗
  12. Impact of interfractional anatomical variation and setup correction methods on interfractional dose variation in IMPT and VMAT plans for pancreatic cancer pati… Last author DOI 10.1002/acm2.12883↗
  13. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective… Co-author DOI 10.1016/j.suronc.2020.10.010↗
  14. Positional repeatability and variation in internal and external markers during volumetric-modulated arc therapy under end-exhalation breath-hold conditions for… Co-author DOI 10.1093/jrr/rraa054↗
  15. Variation in accumulated dose of volumetric-modulated arc therapy for pancreatic cancer due to different beam starting phases. Last author DOI 10.1002/acm2.12720↗
  16. Accumulation of the delivered treatment dose in volumetric modulated arc therapy with breath-hold for pancreatic cancer patients based on daily cone beam compu… Last author DOI 10.1002/mp.13566↗
  17. Evaluation of Dynamic Tumor-tracking Intensity-modulated Radiotherapy for Locally Advanced Pancreatic Cancer. Last author DOI 10.1038/s41598-018-35402-7↗
  18. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Last author DOI 10.1186/s13014-018-1063-5↗
  19. Comparative evaluation of respiratory-gated and ungated FDG-PET for target volume definition in radiotherapy treatment planning for pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.07.012↗
  20. Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.09.016↗
  21. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable progn… Co-author DOI 10.1007/s00066-014-0610-8↗
  22. Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose… Co-author DOI 10.1118/1.4773033↗
  23. Interfractional dose variations in intensity-modulated radiotherapy with breath-hold for pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2011.01.050↗
  24. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer pat… Co-author DOI 10.1016/j.ijrobp.2011.12.026↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michio Yoshimura · 16 shared papers, 2014–2025 · strength 2.62
  2. Mitsuhiro Nakamura · 16 shared papers, 2012–2025 · strength 2.38
  3. Ryo Ashida · 9 shared papers, 2018–2025 · strength 1.45
  4. Takahiro Iwai · 4 shared papers, 2023–2025 · strength 0.89
  5. Ayaka Ogawa · 4 shared papers, 2023–2025 · strength 0.86
  6. Toshihiko Masui · 5 shared papers, 2018–2025 · strength 0.66
  7. Masahiro Hiraoka · 9 shared papers, 2012–2025 · strength 0.64
  8. Masashi Kanai · 5 shared papers, 2015–2025 · strength 0.60
  9. Kazuyuki Nagai · 4 shared papers, 2020–2025 · strength 0.59
  10. Etsuro Hatano · 3 shared papers, 2022–2025 · strength 0.48
  11. Akihisa Fukuda · 3 shared papers, 2022–2025 · strength 0.48
  12. Makoto Sasaki · 3 shared papers, 2019–2023 · strength 0.44
  13. Shinji Üemoto · 4 shared papers, 2014–2023 · strength 0.42
  14. Kyoichi Takaori · 5 shared papers, 2014–2022 · strength 0.39
  15. Megumi Nakao · 2 shared papers, 2021 · strength 0.34
  16. Akira Nakamura · 7 shared papers, 2012–2018 · strength 0.33
  17. Lukas Fabrizio Klassen · 1 shared paper, 2025 · strength 0.27
  18. Keiko Shibuya · 6 shared papers, 2012–2018 · strength 0.26
  19. Katsuyuki Karasawa · 1 shared paper, 2025 · strength 0.25
  20. Yökö Gotö · 3 shared papers, 2018–2019 · strength 0.24
  21. Yuichiro Uchida · 2 shared papers, 2020–2022 · strength 0.23
  22. Naozo Sugimoto · 2 shared papers, 2019–2020 · strength 0.22
  23. Kei Yamane · 1 shared paper, 2025 · strength 0.21
  24. Tetsuya Matsuda · 1 shared paper, 2021 · strength 0.19
  25. Takahiro Kishi · 3 shared papers, 2015–2018 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.